Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Incyte Corporation (INCY) rating of âBuyâ was reiterated today at Nomura with a price target increase of $146 from $126 (versus a $120.83 previous close). In the past 52 weeks, shares of INCY have traded between a low of $43.86 and a high of $133.62 and are now trading at $108.65.ncyte Corporation (INCY) rating of âBuyâ was reiterated today at Nomura with a price target increase of $146 from $126 (versus a $120.83 previous close). In the past 52 weeks, shares of INCY have traded between a low of $43.86 and a high of $133.62 and are now trading at $108.65.